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OBJECTIVES:Deaths due to opioid over-dosage have increased over the last decade
and now represent the most frequent cause of death due to poisoning. This study
examined the temporal association between prescription opioid use between 2000
and 2005 and the number of opioid-poisoning deaths. METHODS: The number of
annual opioid-poisoning deaths from 2000-05was obtained from theNational Vital
Statistics System multiple causes of injury mortality files (Warner 2009). Data for
annual prescription opioid use was obtained from a published study that reported
opioid use from 2.7 to 3.8 million enrollees annually using the HealthCore Blue
Cross and Blue Shield national commercial insurance plans (Sullivan 2008). The
temporal relationship between several opioid use measures and the number of
opioid deaths/year was studied using ordinary least square regression. RESULTS:
The cumulative opioid dose among all recipients increased from204mgsmorphine
equivalents/enrollee/year to 371 mgs and among opioid users with a non-cancer
pain diagnosis from 2473mgs to 3406mgs. During this period, the number of yearly
opioid deaths increased from4,419 in 2000 to 10,947 in 2005. Therewas a significant
linear relationship between the cumulative yearly opioid dose/enrollee/year and
the number of opioid-poisoning deaths (p0.0001, R20.98). A significant positive
linear relationshipwas also observed between thenumber of annual opioid-related
deaths and opioid use measures of cumulative yearly opioid dose (p0.0001,
R20.98), opioid dose/prescription (p0.0053, R20.88) and mean days-supplied of
opioids/year (p0.0001, R20.99). CONCLUSIONS: A strong linear relationship be-
tween opioid-poisoning deaths and several prescription opioid use measures sug-
gests that the acquisition of prescribed opioids through legal channels is associated
with the national opioidmortality rate. This calls for added vigilance on the part of
prescribers and policy makers to ensure safe use of opioid analgesics. Further
research is warranted to confirm these correlations.
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OBJECTIVES: Essential Medicine policy is a important component of China’s un-
dergoing healthcare reform,while the essential medicine list(the “EML”) is the core
of the essential medicine policy. On August 18, 2009, China issued national essen-
tial medicine list (the “NEML”,1st edition) with 205 western medicines and 102
traditional Chinese medicines(the “TCM”) in it, and each province can add further
medicines to the NEML to form its own provincial essential medicine list (the
“PEML”) under specific circumstances. This paper aims at supporting for the next
round adjustment of the NEML through analyzing the situation of addition to the
NEML by each province. METHODS: To study the addition to the NEML by each
province, this paper analyzes the number of medicines added to NEML in all 31
provincial regions in china during the period of August 18, 2009 to January 1, 2011
through searching the official websites, spot investigation and interview the
officials. RESULTS: (1) So far there are 18 provincial regions having added further
medicines to the EML; (2) Regardless of folk medicine, the average number of es-
sential medicines added in each province is 187,among which western medicines
added 115 while the TCM added 72. (3) Shanghai added the largest number of
medicines to its PEML, i.e. 381,while Qinghai Province added the smallest number
of 60. (4)Some autonomous regions added folk medicines to the PEML according to
the local conditions. CONCLUSIONS: (1) it’s necessary for China to adjust the
NEML(1st edition) reasonably based on the number ofmedicines added to the PEML
and drug using characteristics in each province;(2)The more developed the econ-
omy, the more the further essential medicines added, which leads to unfair and
lower the accessiblity to essential medicines in poor areas, thus the government
should increase investment in poor areas.
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OBJECTIVES: To assess the influence of a quality improvement initiative on the
rate of potentially inappropriate medications (PIMs) in primary care elderly
patients.METHODS: A 3-year, multi-phase prospective demonstration project tar-
geting all 303 general practitioners (GPs) in the Local Health Authority (LHU) of
Parma, Italy, was established in 2007. A panel of Parma LHUexperts developed a list
of PIMs deemed to be always avoided for older patients according to the literature.
The quality improvement intervention delivered to GPs hinged upon increasing
physicians’ awareness of prescribing for the elderly and included three key ele-
ments: i) the initial dissemination of the developed PIMs list, along with a list of
alternative drugs to PIMs; ii) annual reviews of PIMs prevalence data; and (iii) a
series of educational sessions on PIMs via academic detailing and case studies
reviews.We used a pre-post design to analyze the change in quarterly rates of PIMs
in elderly patients aged 365 years in Parma LHU between the study start (pre-
intervention - 2007 fourth quarter (Q4)) and the end of the study (post-intervention
– 2009 Q4), using a neighboring LHU similar in size as a comparator. RESULTS: The
prescription rate of PIMs in the elderly of Parma LHU declined by 19%, from 6.3%
pre-intervention (2007 Q4) to 5.1% post-intervention (2009 Q4), compared to a 12%
reduction in the same time period in the comparator LHU, from 6.8% to 5.9%. The
degree of decline in the rate of PIMs was significantly greater in the LHU of Parma
(Breslow-Day test, p0.004). CONCLUSIONS: A quality intervention program look-
ing at improving knowledge in primary care physicians on prescribing for the el-
derly patients resulted in a substantial reduction of the rate of PIMs. Additional
approaches targeting specific medications or physician characteristics should be
developed to further reduce PIMs rates.
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OBJECTIVES: Pharmaceutical cost containment policies can affect access to med-
icines. The present study compares medicines licensed in the United States (US),
United Kingdom (UK), Australia and New Zealand (NZ), and subsidized by the US
Department of Veterans Affairs National Formulary (VANF), UK National Health
Service (NHS), Australian Pharmaceutical Benefits Scheme (PBS) and NZ’s PHARMAC.
We compare licensed and subsidized medicines in terms of: (i) total numbers of
entities (unique ATC codes), (ii) times since first registration (“age”) of entities, and
(iii) numbers of innovative entities. METHODS: All products listed in a major pre-
scribing reference text in each country were classified by ATC code and their reg-
istration dates recorded. Innovative entities given “fast track” approval by the US
Food and Drug Administration or “breakthrough or substantial improvement” sta-
tus by the Canadian Patented Medicines Review Board were identified. RESULTS:
Of the 918 entities and 64 innovative entities licensed in the US, 505 and 20 respec-
tively were VANF subsidized. In the UK, this was 1020 and 58 (1016 and 58 NHS
subsidized), Australia 879 and 49 (567 and 30 PBS subsidized) andNZ 765 and 39 (503
and 19 PHARMAC subsidized). With the exception of the UK, US licensed entities
were “newer” than elsewhere: US median “age” 6,607 days (VANF 8,203 days, p
0.001), UK 7,319 days (NHS 7,319 days, p 0.903), Australia 7,795 days (PBS 8,065
days, p 0.406), NZ 8,936 days (PHARMAC 10,724 days P0.001). NHS subsidized
entities were “newer” than elsewhere. In the US and NZ, subsidized entities were
significantly “older” than licensed entities. CONCLUSIONS: Different pharmaceu-
tical cost containment policies appear to impact the number and “age” of licensed
and subsidized entities, along with access to innovative entities. The New Zealand
system had the strongest cost containment levers, but subsidised the fewest and
“oldest” entities, and fewest innovative entities.
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OBJECTIVES: The objectives of the survey were to gather information on percep-
tions about biologic agents from payers and providers presently and over the next
18months. Areas of focus included: (1) Perceptions of healthcare reformon biologic
product development, access and reimbursement, and outcomes research require-
ments; (2) Biosimilar pricing; (3) Use of specialty pharmacy providers; (4) Improve-
ments in quality of care, outcomes and costs of target diseases. METHODS: An
online survey was conducted with a select sample of national stakeholders repre-
senting payers and providers during the 4th quarter 2010. RESULTS: Over 80 re-
spondents representing multiple types of payers and providers (ex: health plans,
fed and state government agencies, health systems,) participated in the survey.
Fifty percent (50%) of payers and 30% of providers did not know the percentage of
their organization’s health care spend on biologics, but nearly all knew that their
organization’s health care spend on biologics is increasingly important. Payers and
providers agree (7.7/10 and 7.6/10) that patients will incur more out of pocket ex-
penses for biologics over the next 6-18 months. The 3 greatest areas indicated by
providers and payers for improvement in quality of care and outcomes are: Oncol-
ogy-early stage, RA, and AD. It is perceived that generically interchangeable bio-
similars will be available at an approximate 40% discount. Respondents felt estab-
lishing a value proposition and promoting appropriate use will be key drivers of
importance for biologic agents in the future. Respondents agree that their needs
regarding biologic agents should focus on: outcomes measurement, comparative
effectiveness studies, specialty pharmacy usage, benefit designs, and regulatory
developments through educational initiatives. CONCLUSIONS: Biologics remain a
strong growing area of interest among healthcare stakeholders and monitoring
changes inmarketplace dynamicswith additional research effortswill be key areas
of focus in the future.
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OBJECTIVES: Many countries employ an external reference pricing system where
the price of pharmaceutical is in part governed by the price in selected other coun-
tries thus creating a web of relationships between the prices in different countries.
The objective of this study was to investigate which countries could be considered
the most influential in this network. METHODS: The price referencing pattern
between countries in the European Economic Area was represented as a directed
graphwith each individual country as a node and the existence of price referencing
from one country to another as a directed edge. The importance of each country
was estimated by calculating the eigenvector centrality of each node based on the
adjacency matrix representing the edges of the graph. In an extension, we also
performed an analysis where edges were weighted by the size of the pharmaceu-
tical market in each country. RESULTS:When considering unweighted referencing
between countries, Germany and France were the two most influential countries
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followed by Italy, Spain and Hungary ahead of a group of six countries of about
equal impact. When weighing edges between countries by market size the picture
changed somewhat with Germany still the most important country ahead of Italy,
UK, France and Spain. CONCLUSIONS: Taking the entire web of price referencing
relationships into consideration provides somewhat different conclusions than
just counting the number of countries referencing a single country when assessing
the importance of that particular country. Likewise, when incorporating the mar-
ket size of each country, this gives a different result than just ranking countries by
market size alone.
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OBJECTIVES: Many states have implemented prescription drug monitoring pro-
grams (PDMPs) to address abuse and diversion of controlled substances. While the
perceptions of prescribers and dispensers have been examined, the patient per-
spective on PDMPs is notably absent from existing research. This project examined
patient perceptions of Kentucky’s PDMP by asking Medicaid beneficiaries about
their experienceswith the Kentucky All Schedule Prescription Electronic Reporting
program (KASPER). METHODS: Medicaid beneficiaries over age 18 were contacted
by mail to complete a modified version of the Consumer Assessment of Health
Plans Survey. A reminder postcard and second survey was sent to non-responders
two weeks after the first mailing. 1,305 surveys were returned (n5,297, response
rate24.64%). Responses were coded and 25% of surveys were re-coded to test
inter-coder reliability. Statistical analysis was conducted in STATA v11.0.
RESULTS: Of 461 respondents, 63 (13.67%) reported that their health care provider
had discussed their KASPER report with them. Fewer respondents reported that
KASPER prevented them from getting (8.11%) or filling (8.53%) a prescription. Pa-
tients with chronic pain conditions weremore likely to have a health care provider
discuss a KASPER report with them (10.18%) than non-chronic pain patients
(3.95%). Chronic pain patients were also more likely to report that a KASPER report
prevented them from getting a prescription than non-chronic pain patients (6.01%
vs. 1.75%). Chi-square testing demonstrates that these differences are statistically
significant (discussed KASPER report p0.006; KASPER report prevented getting
prescription p0.013). There were limited differences in patient-reported experi-
ences with KASPER based upon patient gender, race, Hispanic ethnicity, or educa-
tion level. CONCLUSIONS: Most respondents report they are unaffected by the
KASPER program. Respondents with chronic pain are significantly more apt to
report difficulty getting and filling prescriptions. States seeking to form or alter
PDMPs should consider patient input as well as prescriber and dispenser opinions.
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OBJECTIVES: To examine whether R&D for medical products differs from other
forms of R&D and should therefore be guided by different policy solutions in at-
tempting to stimulate it.METHODS: Conceptual analysis and regression analysis.
RESULTS:We argue that, as opposed to standard products, there is a link between
output markets and devlopment of medical products in the sense that the cost
developing newmedical products depends on the quality and price of conventional
care in output markets. This is because clinical trials are the major driver of devel-
opment costs and that recruitment of subjects into trials requires them to forego
conventional care. This output market link induces non-standard effects on med-
ical R&D costs and innovative returns. First, medical R&D has a self-limiting effect
because high quality innovationsmake future developmentmore difficult through
prolonged recruitment. Second, outputmarket policies, such as universal coverage
and price controls, have not only demand-side effects on R&D, but also supply side
effects by altering the cost of development. Third, in contrast with other product
markets, the development spending in a country may not be driven by its relative
R&D talent but by output market policies. We consider evidence of the discussed
link between output markets and development for the break-through HIV thera-
pies introduced on the market in 1996. We document a dramatic drop of 35% in
yearly trial recruitment induced by these new innovations, slowing down develop-
ment and lowering innovative returns. CONCLUSIONS: We argue that the the fu-
ture efficinecy analysis of various forms of health policy in output markets should
be evaluated in terms of how it affects development incentives.
PHP19
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OBJECTIVES: Montelukast has been approved for the prophylaxis and chronic
treatment of asthma in patients 12months and older, acute prevention of exercise
induced bronchospasm in patients 15 years and older and relief of symptoms of
seasonal and perennial allergic rhinitis in patients as young as 6 months. We
examined trends inmontelukast use, new use, and on-label and off-label use from
1998 to 2008. METHODS: In this retrospective cohort study of administrative
claims, eligible subjects in the Lifelink database between January 1997 and Decem-
ber 2009 were analyzed. Study subjects had to be continuously enrolled for two
years. On label use was determined by searching for ICD-9-CM codes for approved
indications; asthma, exercise induced bronchospasm, and allergic rhinitis. OLS
regression was used to assess linear trends over time. RESULTS: 0.16% of subjects
were prescribed montelukast in 1998 and 2.44% in 2008 and the linear trend of
increase in use was significant (R20.978, p0.0001). 37,793 subjects were eligible
for the analysis of off-label usewith amean age of 31.22 years and 43.6%weremale.
Off-label use was lowest in 1999 (12.56%) and highest in 2007 (24.54%) with a sig-
nificant increasing trend (R20.5776, p0.0066) but it increased more modestly
from 2002 (20.6%) to 2008 (23.91%). Overall 23.02% of subjects usedmontelukast off
label and the elderly (31.45%) and persons from the south (28.16%) had the highest
rates of montelukast off label use. CONCLUSIONS: Montelukast prescribing in-
creased substantially over the previous decade where in 2008, 1 in 40 persons with
commercial insurance had at least one prescription filled. Over three quarters of
montelukast prescribing is supported by a diagnosis for a labeled indication. Off
label use is greatest in the elderly which may be partially explained by more evi-
dence based off label uses in the literature for adults.
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OBJECTIVES:Understanding the characteristics and distribution of inpatients who
have basic medical insurance within China, Analyzing the treatment status and
inpatients’ expenses, Studying and summarizing the application of various kinds
of medication, Providing database to government for supporting drug regulatory
policy .METHODS:We conducted a sampling survey of inpatients with basic med-
ical insurance in all the provinces in China by city. In 2010, we extracted data of
157,577 inpatients, and accounting for 0.5% of the total sample size. The sampled
data was statistically analyzed by SQL Server 2003. RESULTS: Average hospital
expenses per visit increased rapidly while drug expenses remained high. In 2009,
the average hospital expense of inpatients with basic medical insurance reached
RMB7,670 Yuan per visit, a 13.6% increased from the previous year. The drug ex-
pense was accounted for 49.1% of the total. Overall the spectrum of diseases of
inpatients is stable while the proportion of tumor patients was increasing. In 2009,
among those inpatients afflicted by various diseases, the Cardiovascular system
diseases accounted for 26.75%, which still kept the first position, and Tumors ac-
counted for 12.35% (10.95% in 2008). CONCLUSIONS: 1)Effects from the aging pop-
ulation, the health insurance fund spentmostly on the elderly, aremore obvious. In
2009, among urban basic medical insured people, inpatients that are over sixty
accounted for 49.2%, with 55.26% of the total expense. 2) The Medical Insurance
Fundhad a high concentration of resource use. In 2009, 9.3% of the drugs accounted
for 80% the total drug expense. 3) The rational use of drugs is not optimistic. The
expense of antibiotic medicines accounted for 29.3% of the total expense of chem-
ical medicines, the number of the inpatients that have taken conbinational antibi-
otics accounted for 63.7% of the total inpatients. Abuse of Traditional-Chinese-
Medicine-injection and drugs for adjuvant-treatment also needs to be monitored.
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OBJECTIVES: To examine the association of self-reported health status with cost-
related medication nonadherence (CRN), as well as with prescription drug out-of-
pocket spending (OOP) among senior Medicare enrollees.METHODS:We analyzed
the 2008 Health and Retirement Study (HRS), a national survey of adults aged 50 or
older. Self-reported health status was classified into three categories: excellent
(excellent and very good), good, and poor (fair and poor) health. We estimated the
association between self-report health status and 1) cost-related medication non-
adherence using Logistic regression; 2) monthly out-of-pocket pharmacy spending
using generalized linearmodel (GLM) controlling for socio-demographic character-
istics and physical health conditions. All estimates were weighted to be nationally
representative. RESULTS: Among 9,090 Medicare beneficiaries aged 65 or older
(mean age 74.7 years), 56.1% were female, 5.8% reported taking less medication
because of cost. Compared to those with excellent health status, beneficiaries with
good health (OR1.643, p0.0001, 95% confidence interval [CI] 1.263-2.138) and
poor health (OR2.947, p0.0001, 95% CI 2.264-3.834) were more likely to report
cost-related medication nonadherence. The GLM regression results showed that
compared to excellent health beneficiaries, the average monthly out-of-pocket
pharmacy spending was $13.844 (p0.0001, 95% CI 7.500-20.186) higher for good
health and $27.245 (p0.0001, 95%CI 17.695-36.794) higher for poor health subjects.
CONCLUSIONS:Drug spending is heavily concentrated among individuals 65 years
or older and cost-relatedmedication underuse among seniors has been a big public
health concern, especially before the implementation of Medicare Part D in 2006.
This study find that worse health status is significantly associated with increased
likelihood of cost-related medication nonadherence and higher out-of-pocket ex-
penditures for prescription drugs. Senior Medicare beneficiaries with poor health
still faced higher OOP burden compared with their healthy counterparts.
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THE IMPACT OF MEDICARE PART D ON PRESCRIPTION VOLUME AND
OUT-OF-POCKET COSTS OF MEDICALLY NECESSARY DRUGS
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OBJECTIVES: With the January 2006 introduction of Medicare Part D Plans (PDP)
intended to increase drug access, we hypothesized that it would impact trends in
prescription volume (TRx) and out-of-pocket costs (OPC). We evaluated these un-
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